Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of relatlimab plus nivolumab with chemotherapy versus nivolumab with chemotherapy in first-line stage IV or recurrent NSCLC
2020-004026-31Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing relatlimab + nivolumab + chemotherapy with nivolumab + chemotherapy (2 arms). Started Dec 2020; status: active.
02
Drugs
relatlimabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004026-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004026-31.